• Something wrong with this record ?

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure

P. Mease, A. Deodhar, R. Fleischmann, J. Wollenhaupt, D. Gladman, P. Leszczyński, P. Vitek, A. Turkiewicz, M. Khraishi, O. FitzGerald, R. Landewé, M. de Longueville, B. Hoepken, L. Peterson, D. van der Heijde,

. 2015 ; 1 (1) : e000119. [pub] 20150625

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc16000903

OBJECTIVE: Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with psoriatic arthritis (PsA), including patients with prior antitumour necrosis factor (TNF) therapy. We report efficacy and safety data from a 96-week data cut of RAPID-PsA. METHODS: RAPID-PsA was placebo-controlled to week 24, dose-blind to week 48 and open-label to week 216. We present efficacy data including American College of Rheumatology (ACR)/Psoriasis Area and Severity Index (PASI) responses, HAQ-DI, pain, minimal disease activity (MDA), modified total Sharp score (mTSS) and ACR responses in patients with/without prior anti-TNF exposure, in addition to safety data. RESULTS: Of 409 patients randomised, 273 received CZP from week 0. 54 (19.8%) CZP patients had prior anti-TNF exposure. Of patients randomised to CZP, 91% completed week 24, 87% week 48 and 80% week 96. ACR responses were maintained to week 96: 60% of patients achieved ACR20 at week 24, and 64% at week 96. Improvements were observed with both CZP dose regimens. ACR20 responses were similar in patients with (week 24: 59%; week 96: 63%) and without (week 24: 60%; week 96: 64%) prior anti-TNF exposure. Placebo patients switching to CZP displayed rapid clinical improvements, maintained to week 96. In patients with ≥3% baseline skin involvement (60.8% week 0 CZP patients), PASI responses were maintained to week 96. No progression of structural damage was observed over the 96-week period. In the Safety Set (n=393), adverse events occurred in 345 patients (87.8%) and serious adverse events in 67 (17.0%), including 6 fatal events. CONCLUSIONS: CZP efficacy was maintained to week 96 with both dose regimens and in patients with/without prior anti-TNF exposure. The safety profile was in line with that previously reported from RAPID-PsA, with no new safety signals observed with increased exposure. TRIAL REGISTRATION NUMBER: NCT01087788.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000903
003      
CZ-PrNML
005      
20160520110857.0
007      
ta
008      
160108s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/rmdopen-2015-000119 $2 doi
035    __
$a (PubMed)26509074
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mease, P $u Swedish Medical Center and University of Washington , Seattle, Washington , USA.
245    10
$a Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure / $c P. Mease, A. Deodhar, R. Fleischmann, J. Wollenhaupt, D. Gladman, P. Leszczyński, P. Vitek, A. Turkiewicz, M. Khraishi, O. FitzGerald, R. Landewé, M. de Longueville, B. Hoepken, L. Peterson, D. van der Heijde,
520    9_
$a OBJECTIVE: Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with psoriatic arthritis (PsA), including patients with prior antitumour necrosis factor (TNF) therapy. We report efficacy and safety data from a 96-week data cut of RAPID-PsA. METHODS: RAPID-PsA was placebo-controlled to week 24, dose-blind to week 48 and open-label to week 216. We present efficacy data including American College of Rheumatology (ACR)/Psoriasis Area and Severity Index (PASI) responses, HAQ-DI, pain, minimal disease activity (MDA), modified total Sharp score (mTSS) and ACR responses in patients with/without prior anti-TNF exposure, in addition to safety data. RESULTS: Of 409 patients randomised, 273 received CZP from week 0. 54 (19.8%) CZP patients had prior anti-TNF exposure. Of patients randomised to CZP, 91% completed week 24, 87% week 48 and 80% week 96. ACR responses were maintained to week 96: 60% of patients achieved ACR20 at week 24, and 64% at week 96. Improvements were observed with both CZP dose regimens. ACR20 responses were similar in patients with (week 24: 59%; week 96: 63%) and without (week 24: 60%; week 96: 64%) prior anti-TNF exposure. Placebo patients switching to CZP displayed rapid clinical improvements, maintained to week 96. In patients with ≥3% baseline skin involvement (60.8% week 0 CZP patients), PASI responses were maintained to week 96. No progression of structural damage was observed over the 96-week period. In the Safety Set (n=393), adverse events occurred in 345 patients (87.8%) and serious adverse events in 67 (17.0%), including 6 fatal events. CONCLUSIONS: CZP efficacy was maintained to week 96 with both dose regimens and in patients with/without prior anti-TNF exposure. The safety profile was in line with that previously reported from RAPID-PsA, with no new safety signals observed with increased exposure. TRIAL REGISTRATION NUMBER: NCT01087788.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Deodhar, A $u Oregon Health & Science University , Portland, Oregon , USA.
700    1_
$a Fleischmann, R $u University of Texas SW Medical Center , Dallas, Texas , USA.
700    1_
$a Wollenhaupt, J $u Schoen Klinik , Hamburg , Germany.
700    1_
$a Gladman, D $u Toronto Western Research Institute , Toronto , Canada.
700    1_
$a Leszczyński, P $u Poznan Medical University , Poznan , Poland ; Division of Rheumatology and Osteoporosis , Jozef Strus Hospital , Poznan , Poland.
700    1_
$a Vitek, P $u PV-MEDICAL, Revmavita Centre , Zlin , Czech Republic.
700    1_
$a Turkiewicz, A $u Rheumatology Associates Clinical Research Unit , Birmingham, Alabama , USA.
700    1_
$a Khraishi, M $u Department of Medicine , Memorial University of Newfoundland , St. John's , Canada.
700    1_
$a FitzGerald, O $u Department of Rheumatology , St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College , Dublin , Ireland.
700    1_
$a Landewé, R $u Academic Medical Center, Amsterdam and Atrium Medical Center , Heerlen , The Netherlands.
700    1_
$a de Longueville, M $u UCB Pharma , Brussels , Belgium.
700    1_
$a Hoepken, B $u UCB Pharma , Monheim , Germany.
700    1_
$a Peterson, L $u UCB Pharma , Raleigh, North Carolina , USA.
700    1_
$a van der Heijde, D $u Leiden University Medical Centre , Leiden , The Netherlands.
773    0_
$w MED00188812 $t RMD open $x 2056-5933 $g Roč. 1, č. 1 (2015), s. e000119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26509074 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20160520111010 $b ABA008
999    __
$a ind $b bmc $g 1103184 $s 925109
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 1 $c 1 $d e000119 $e 20150625 $i 2056-5933 $m RMD open $n RMD Open $x MED00188812
LZP    __
$a Pubmed-20160108

Find record

Citation metrics

Archiving options